Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 6179.

https://doi.org/10.1182/blood-2023-173085

Published: 2023

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustin in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report

Andrea Gallamini, MD, Alessandro Rambaldi, MD, Fontanet Bijou, MD, Aurore Perrot, MD, Caterina Patti, MD, Lauris Gastaud, MD, Roberto Sorasio, MD, Colin Debaigt, Emmanuel Chamorey, Simonetta Viviani, MD, Antoine Thyss, MD

Blood (2016) 128 (22): 4154.

https://doi.org/10.1182/blood.V128.22.4154.4154

Published: 2016

Journal Articles

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

Luisa Giaccone, Andrea Evangelista, Francesca Patriarca, Roberto Sorasio, MD, Massimo Pini, MD, Fabrizio Carnevale Schianca, MD, Moreno Festuccia, Lucia Brunello, Francesco Zallio, MD, Enrico Maffini, Paola Omedè, PhD, Sara Bringhen, MD, Nicola Mordini, MD, Renato Fanin, MD, Massimo Massaia, MD, Antonio Palumbo, MD, Giovannino Ciccone, MDPhD, Mario Boccadoro, MD, Benedetto Bruno, MD PhD

Blood (2016) 128 (22): 3469.

https://doi.org/10.1182/blood.V128.22.3469.3469

Published: 2016

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Anna Guidetti, MD, Silvia Locatelli, PhD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Domenico Russo, Pietro Bulian, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Andrea Anichini, PhD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 3705.

https://doi.org/10.1182/blood.V118.21.3705.3705

Published: 2011

Journal Articles

Cost-Effectiveness of Interim PET Response Adapted Therapy In ABVD-Treated, Advanced-Stage Hodgkin Lymphoma

Andrea Gallamini, MD, Monia Marchetti, Anna Borra, Roberto Sorasio, MD, Francesca Fiore

Blood (2011) 118 (21): 1563.

https://doi.org/10.1182/blood.V118.21.1563.1563

Published: 2011

Journal Articles

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Blood (2011) 117 (24): 6721–6727.

https://doi.org/10.1182/blood-2011-03-339945

Published: 2011

Journal Articles

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Simonetta Viviani, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Stefania Zambelli, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 2861.

https://doi.org/10.1182/blood.V116.21.2861.2861

Published: 2010

Journal Articles

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Blood (2010) 116 (21): 525.

https://doi.org/10.1182/blood.V116.21.525.525

Published: 2010

Journal Articles

Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

Blood (2010) 116 (21): 1254.

https://doi.org/10.1182/blood.V116.21.1254.1254

Published: 2010

Journal Articles

Comparative Assessment of Different Criteria for Interim-PET Interpretation in a Cohort of Hodgkin Lymphoma Patients Treated in a Single Center.

Andrea Gallamini, MD, Stephane Chauvie, Francesca Fiore, MD, Roberto Sorasio, MD, Flavia Salvi, MD, Andrea Bianchi, MD, Alberto Biggi, MD

Blood (2009) 114 (22): 3657.

https://doi.org/10.1182/blood.V114.22.3657.3657

Published: 2009

Journal Articles

Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.

Luisa Giaccone, Moreno Festuccia, Roberto Sorasio, Nicola Mordini, Fabrizio Carnevale Schianca, Francesca Patriarca, Marco Casini, Anna Paola Iori, Robin Foà, Mario Boccadoro, Benedetto Bruno

Blood (2009) 114 (22): 4330.

https://doi.org/10.1182/blood.V114.22.4330.4330

Published: 2009

Journal Articles

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Blood (2009) 113 (14): 3375–3382.

https://doi.org/10.1182/blood-2008-07-167379

Published: 2009

Journal Articles

Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies

Benedetto Bruno, Roberto Sorasio, Silvia Cena, Christian Sfiligoi, Luisa Giaccone, Marcella Spagnolo, Milena Gilestro, Fulvia Giaretta, Rainer F. Storb, Paola Omedè, Mario Boccadoro

Blood (2008) 112 (11): 4344.

https://doi.org/10.1182/blood.V112.11.4344.4344

Published: 2008

Journal Articles

RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLATyping and Donor Availability

Barbara Sarina, MD, Luca Castagna, MD, Fabio Benedetti, MD, Francesca Patriarca, MD, Michele Malagola, MD, Silvia Ferrari, MD, Roberto Sorasio, MD, Lucia Farina, MD, Enrico Morello, MD, Alessandro Bonini, MD, Nicola Mordini, MD, Sergio Tamiazzo, MD, Michele Falda, MD, Laura Giordano, PhD, Paolo Corradini, MD

Blood (2008) 112 (11): 460.

https://doi.org/10.1182/blood.V112.11.460.460

Published: 2008

Journal Articles

The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .

Lucia Farina, Benedetto Bruno, Francesca Patriarca, Francesco Spina, Roberto Sorasio, Mara Morelli, Renato Fanin, Mario Boccadoro, Paolo Corradini, MD

Blood (2008) 112 (11): 2144.

https://doi.org/10.1182/blood.V112.11.2144.2144

Published: 2008

Journal Articles

Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment

Ermanno Venturino, MD, Dario Ferrero, MD, Elena Crisà, MD, Mario Bazzan, MD, Ausilia Ciocca, MD, Roberto Sorasio, MD, Valentina Giai, MD, Mariella Genuardi, MD, Mario Boccadoro, MD

Blood (2008) 112 (11): 5229.

https://doi.org/10.1182/blood.V112.11.5229.5229

Published: 2008

Journal Articles

Risk of Hepatitis B and Efficacy of Treatment with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplant.

Luisa Giaccone, MD, Alfredo Marzano, MD, Isabel Resta, Andrea Marengo, Francesca Fiore, MD, Roberto Sorasio, MD, Moreno Festuccia, Mario Rizzetto, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 1970.

https://doi.org/10.1182/blood.V110.11.1970.1970

Published: 2007

Journal Articles

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Blood (2006) 108 (11): 3158.

https://doi.org/10.1182/blood.V108.11.3158.3158

Published: 2006

NARROW

Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

A PHASE 1/2 Clinical Trial of Brentuximab-Vedotin and Bendamustin in Elderly Patients with Previously Untreated Advanced Hodgkin Lymphoma (HALO STUDY. NCT identifier : 02467946): Preliminary Report

Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Cost-Effectiveness of Interim PET Response Adapted Therapy In ABVD-Treated, Advanced-Stage Hodgkin Lymphoma

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma

Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

Comparative Assessment of Different Criteria for Interim-PET Interpretation in a Cohort of Hodgkin Lymphoma Patients Treated in a Single Center.

Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies

RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLATyping and Donor Availability

The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .

Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment

Risk of Hepatitis B and Efficacy of Treatment with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplant.

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only